815 results about "Gastrointestines" patented technology

The invention discloses a probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as a preparation method and application thereof, and belongs to the field of biological medicines. The FCPs and hyaluronic acid (HA) are combined through non-covalent interaction, so that the hydrogel has colon targeting property and mucosal adhesion at the same time, and delivery of probiotics is facilitated. The hydrogel (HF) based on polysaccharide has good biocompatibility, and can be used for effectively encapsulating the probiotics and the natural products. Then, the PDA-TH NPs and BA are incorporated into the polysaccharide chain network of HF, and finally the BA-HF-PDAT targeted co-delivery system is constructed. The BA (at) HF-PDAT targeted co-delivery system can protect BA from serious gastrointestinal stress, and is jointly assembled with PDT-TH NPs to realize dual slow release of thymol (Thy), so that the treatment effect of BA and Thy is improved, and the BA (at) HF-PDAT targeted co-delivery system contributes to treatment of clostridium difficile infection (CDI).

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The invention provides a halite-containing probiotic preparation for improving gastrointestinal environment and a preparation method, the halite-containing probiotic preparation comprises the following components in parts by weight: 60-70 parts of a probiotic composition, the probiotic composition comprises lactobacillus casei Zhang, animal bifidobacterium subsp. Lactis V9, lactobacillus plantarum P-01, animal bifidobacterium subsp. Lactis B-01 and casei paracasei LC-11, the weight ratio is 3: 2: 2: 1: 1. 1.2 to 3.5 parts of nanoscale refined halite; 10 to 15 parts of a microcapsule embedding material; 0.6 to 1.2 parts of an antioxidant system; 15 to 30 parts of auxiliary materials; the probiotic preparation disclosed by the invention has the characteristics of obvious strain combination advantage, nano-scale halite protection and synergism, accurate release of a multi-layer microcapsule structure, synergistic effect of an antioxidant system and the like, the survival rate of probiotics, gastrointestinal tract tolerance and intestinal colonization capacity are remarkably improved, and a new technical scheme is provided for improving gastrointestinal health.

Embodiments of devices and methods for collecting gastrointestinal samples using a capsule-shaped device that is swallowed are provided.

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The present disclosure provides batteries that have a reduced risk or no risk of esophageal or gastrointestinal damage in a conductive aqueous environment, such as when accidentally swallowed. The batteries are, in some embodiments, nominally 9V, 3V or 1.5V coin or button cell-type batteries.

Compositions and methods for detecting gastrointestinal diseases are provided. The present invention relates to compositions and methods for detecting and treating gastrointestinal diseases. The present invention relates to the use of an agent for determining intestinal alkaline phosphatase (iAP) activity and the amount of iAP in a child for the preparation of a kit for use in a method for determining the prognosis of inflammatory bowel disease (IBD) in said child.

The invention relates to a feeding intolerance burst risk early warning method and device based on multi-modal dynamic monitoring. The method comprises the steps that a gastrointestinal tract peristaltic wave image sequence under the abdominal skin surface of a patient is collected; collecting borborygmus data; collecting physical sign physiological data of the patient; monitoring behavior and posture data of the patient in real time; tracking the infinitesimal displacement and deformation of the gastrointestinal wall in the gastrointestinal tract peristaltic wave image sequence, and extracting and quantifying the speed, direction and wave crest and trough change rate of the peristaltic wave and the regularity index of the peristaltic wave; calculating a physiological deviation degree between the fusion feature at the current moment and an expected normal mode generated by the physiological feature baseline model of the patient; and inputting the physiological deviation degree, the change rate of the physiological deviation degree in the time dimension and the accumulated deviation duration into a conditional variation risk assessment model, and outputting a potential spatial distance. Through the non-invasive and highly quantified feeding intolerance risk model, the early recognition capability and clinical intervention efficiency of feeding intolerance are remarkably improved.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

An apparatus for detecting and treating gastrointestinal pathology. The apparatus includes a wireless capsule, where the wireless capsule includes at least one of: an optical imaging system, a thermal imaging system, or a camera. The camera is a narrow band imaging system, a white light imaging system, or both.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention provides donepezil sustained-release microspheres and a preparation method, a pharmaceutical preparation and application thereof. The preparation method comprises the following steps: forming a water phase (containing a surfactant, an osmotic pressure regulator and water, and regulating the pH value with a pH regulator); forming an oil phase (comprising donepezil, a carrier material and an organic solvent); and adding the oil phase into the water phase, dispersing to form a pre-emulsion, performing membrane emulsification on the pre-emulsion to form an emulsion, and finally curing, washing and freeze-drying the emulsion to obtain the donepezil sustained-release microspheres. The preparation process is stable and controllable, the batch-to-batch repeatability is good, the surface of the microsphere is smooth and complete, the particle size distribution is uniform, the size is controllable, the microsphere has high drug loading capacity, long-term stable release can be realized, the injectability is excellent, the administration frequency can be reduced, and the adverse reaction of gastrointestinal tracts can be reduced.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

Provided are a new polypeptide for repairing mucosal damage or a skin wound, and the use thereof. The polypeptide is not homologous with known polypeptides, can be stably present in vivo and in vitro, and has the effect of regulating stem cell proliferation and differentiation to repair mucosal damage or a skin wound. The present invention further relates to the use of the new polypeptide in the repairing of mucosal damage or a skin wound by means of regulating stem cell proliferation and differentiation, and the use thereof in the prevention, alleviation or treatment of gastrointestinal diseases.

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The invention belongs to the technical field of medical image processing, and provides a multi-modal medical image analysis system, medium and equipment for gastrointestinal disease recognition, and the technical scheme is as follows: extracting multi-scale texture features and structural features of a gastrointestinal endoscopy color image and a gastrointestinal endoscopy OCT depth image respectively, and fusing to obtain a cross-modal feature sequence; based on the feature sequence added with the position code, learning a spatial corresponding relation of different modal data on blood vessel morphology and gastrointestinal tract wall interlayer structure; obtaining a multi-scale global context feature sequence and a local detail feature sequence based on the aligned cross-modal blood vessel and gastrointestinal tract wall interlayer structure features, and fusing the multi-scale global context feature sequence and the local detail feature sequence to obtain fused multi-modal features; obtaining an adjusted dense deformation field based on the fused multi-modal features; and performing coarse registration and fine registration based on the adjusted dense deformation field to obtain a registered gastrointestinal endoscopy color image and a registered gastrointestinal endoscopy OCT depth image. The anti-interference capability is strong, and the data stability is high.

The present invention is directed to novel compounds that inhibit Nav1.8 sodium channels, methods of making, and methods of using thereof. The present disclosure is further directed to administering the disclosed compounds as therapeutic solutions for chronic pain, primary pain, idiopathic pain, gastrointestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer-related pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Summer-Marr-Tuff syndrome, incontinence, pathological cough, or arrhythmia to a subject in need thereof.

The present disclosure provides solid forms of sodium chenodeoxycholate (NaCDC), as well as compositions thereof, and methods of use and preparation thereof. In some embodiments, the provided solid forms are useful for treating gastrointestinal disorders, such as constipation (e.g., IBS-C). In some embodiments, the provided solid forms are useful for preparing new formulations of NaCDC, such as formulations uniquely designed to address certain problems of prior formulations of CDCA or salts thereof.

The invention discloses application of 2-hydroxybutyric acid and derivatives thereof in preparation of drugs for preventing and / or treating metabolic diseases, and belongs to the technical field of biological medicines. Experiments prove that the 2-hydroxybutyric acid and the derivatives thereof can effectively inhibit obesity induced by high fat diet and reduce body fat, and have good improvement effects on related glucose and lipid metabolism disorders, including reduction of fasting blood-glucose, improvement of glucose tolerance, reduction of liver lipid deposition and improvement of liver functions. More importantly, the 2-hydroxybutyric acid does not affect ingestion, the metabolism improvement effect of the 2-hydroxybutyric acid depends on activation of fat heat production, and energy consumption can be directly promoted, so that obvious gastrointestinal tract adverse reactions cannot be generated, and potential mental side effects of existing appetite inhibiting drugs do not exist.

Systems and methods for anchoring and restraining gastrointestinal prostheses are disclosed. In various examples, the systems and methods include securing a gastrointestinal device within a patient's anatomy by extending an anti-migration anchor through a plurality of portions of the gastrointestinal device to couple together the plurality of portions of the gastrointestinal device. In some examples, the anti-migration anchor extends through tissue situated between the plurality of portions of the gastrointestinal device.

The invention belongs to the technical field of medical treatment, and discloses an osteoarthritis rehabilitation auxiliary device and system, and the device comprises an intelligent vibration treatment module, a pressure sensor and biological feedback module, an intelligent control and APP remote management module, a pressure sensor, an accelerometer, and a myoelectricity sensor. The joint pain is relieved, vibration can stimulate sensory nerves, pain signal transmission is reduced, and the pain degree is reduced. Vibration promotes secretion of joint fluid, friction is reduced, and the range of motion is improved. Low-frequency vibration stimulates the activity of cartilage cells, and cartilage degeneration is slowed down. And a biological feedback system is intelligently regulated and controlled, so that the treatment accuracy is improved. Non-invasive treatment is achieved, and no side effect exists; gastrointestinal discomfort caused by drug treatment or high cost of long-term physical treatment is avoided. Remote monitoring is achieved, compliance is improved, a patient can be treated at home and does not need to see a doctor frequently, and medical cost is reduced.